ENDPOINTS

Novo Nordisk takes aim at Roche in hemophilia A, but is way behind

Novo Nordisk said Friday that its hemophilia A preventive Mim8 was effective in its pediatric trial, opening it up to a larger patient population after the treatment succeeded in its pivotal ...

Feb 9, 2025 - 21:49
 0
Novo Nordisk takes aim at Roche in hemophilia A, but is way behind
Novo Nordisk said Friday that its hemophilia A preventive Mim8 was effective in its pediatric trial, opening it up to a larger patient population after the treatment succeeded in its pivotal ...
Read More

Tags:

Previous Article

Bain buys Mitsubishi Tanabe Pharma in $3.3B bet on Japan

Next Article

Longtime Sandoz exec announces retirement; Lilly appoints head of India

Related Posts

Acelyrin and Alumis to merge in deal combining cash, assets

Acelyrin and Alumis to merge in deal combining cash, as...

Feb 9, 2025  0

Hims’ Super Bowl ad has drawn ire from lawmakers — and now Novo Nordisk

Hims’ Super Bowl ad has drawn ire from lawmakers — and ...

Feb 10, 2025  0

Merck KGaA confirms interest in acquiring cancer biotech SpringWorks

Merck KGaA confirms interest in acquiring cancer biotec...

Feb 10, 2025  0